Cerexa has completed patient enrollment for its multinational Phase II clinical trial of ceftaroline acetate (formerly PPI-0903) in patients with complicated skin and skin structure infections (cSSSI). Ceftaroline is a next generation, broad spectrum, cephalosporin antibiotic that combines the advantage of an enhanced gram-positive spectrum, including bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA), with broad gram-negative activity. The FDA recently granted ceftaroline fast-track designation for the treatment of cSSSI caused by MRSA.
The trial enrolled 100 patients with cSSSI and was conducted at more than 20 study sites worldwide. The objective of this trial was to investigate the efficacy and safety of ceftaroline versus standard therapy.